# Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

> **NCT00129896** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 73 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Myocet
- **DRUG:** Taxotere
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT00129896
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2008-12
- **Final completion:** 2010-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129896, "Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00129896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*